Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS-5885 with GS-9451, tegobuvir, and ribavirin in treatment-naive genotype 1 chronic hepatitis C
2011-000944-43Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Jun 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ledipasvir, vedroprevir, tegobuvir and ribavirin in hepatitis C virus infection (4 arms), sponsored by Gilead Sciences. Primary endpoint: Sustained virologic response at 24 weeks post-treatment. Started Jun 2011; status: completed.
02
Drugs
ledipasvirvedroprevirtegobuvirribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2011-000944-43.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000944-43.